WASHINGTON — Eli Lilly & Co. said it will push ahead with a first-of-a-kind imaging chemical designed to help screen for Alzheimer’s disease, despite a negative ruling by Medicare officials. The Centers for Medicare and Medicaid Services reported it will not cover the chemical, called Amyvid, which highlights brain plaque in medical imaging scans. The […]

Read the full story